Clinical trial
Effect Of GW501516X On How The Heart Obtains And Uses Energy
NCT00318617 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00318617 |
|---|---|
| Title | Effect Of GW501516X On How The Heart Obtains And Uses Energy |
| Official title | A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Dyslipidaemias, Heart Failure |
| Intervention type | Drug |
| Interventions | GW510516X |
| Enrollment | 30 |
| Start date | Dec 1, 2005 |
| First posted | Apr 27, 2006 |
| Last update posted | Mar 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: